Suxibuzon

Properties / Effects

Suxibuzon is a synthetic, easily digestable precursor (prodrug) of proven drug phenylbutazone. After oral administration, Suxibuzon from the gastro-intestinal tract is absorbed and metabolized in the liver. While phenylbutazone produced with the known anti-inflammatory, analgesic and antipyretic effects. The mechanism of action is based on the inhibition of the enzyme Cyclooxgenase, which is required for the synthesis of prostaglandins. Prostaglandins are involved in the transmission of peripheral pain signals in the development of inflammation.
Suxibuzon is a precursor of gastric phenylbutazone better tolerated than phenylbutazone.

 
Pharmacokinetics

Suxibuzon is rapidly absorbed from the gastrointestinal tract and largely bound to plasma proteins. The metabolism occurs mainly in the liver. This results in phenylbutazone and its metabolites. These are mainly excreted by the kidneys.

 
Indications

Inflammation and pain of the musculoskeletal system, eg for bruises, arthritis, tendonitis, tenosynovitis, bursitis, myositis.

 
Dosage / Application

orally
During two days:
2 x 7.5 mg daily, depending Suxibuzon / kg bw
(Equivalent to 2 times daily 1 Beutel/200 kg bw)
 
While a further 3 days:
2 x 3.75 mg daily Suxibuzon / kg bw
(½ to 2 x daily Beutel/200 kg bw)
 
Then, as needed:
1 x daily or every second Beutel/200 day ½ kg bw
 
The granules administered mixed with food.

 
Application Restrictions

Contraindications
Danilon équidos ® should not be used:
- In animals, which react hypersensitive to the product
- In the presence of
    ● gastritis, gastric and / or duodenal ulcers, enteritis
    ● kidney, liver or heart disease
    ● coagulopathy, hemorrhage, edema, hemoglobinuria or not of inflammatory origin
    ● Dehydration
 
Precautions
Pregnant or lactating mares should not be treated.
During the treatment must be accessible to water ad libitum.
By prolonged treatment the blood count are checked regularly.
If after 2 days of no activity has occurred, treatment should be discontinued and the diagnosis can be verified.

 
Adverse effects

None at the recommended dosage.
In overdose the following symptoms are possible:
- Anorexia, weight loss
- Gastrointestinal disorders (irritation of mucous membranes, colitis, ulcers, diarrhea, blood in the feces)
- Altered blood count and bleeding
- Hypoproteinemia and ventral edema, which can lead to thickening of the blood, hypovolemic shock and cardiovascular collapse
- Kidney failure
- Allergic reactions
Should such symptoms occur, treatment should be discontinued.
A slow infusion of sodium bicarbonate promotes the excretion of phenylbutazone.
Ponies are more sensitive to phenylbutazone as a horse.

 
Waiting periods

Horse withdrawal time: 6 months
In horses intended for the production of foodstuffs, following the last treatment a withdrawal period of 6 months for milk and edible tissues comply. For drug treatment, there is a documentation requirement. In horses, which are not intended for production of food, which accounted for the withdrawal time information.

 
Interactions

Can occur with the concomitant use of corticosteroids, barbiturates, anticoagulants, sulphonamides or chloramphenicol (induction of liver enzymes or displacement from plasma protein binding).

 
Other notes

- At room temperature (15 ° C - 25 ° C) and stored protected from moisture.
- This medicine should only be used up to the container with the "Exp" designated date.
- Medication, keep out of reach of children.

 
Special arrangements